Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial).
Akihito KawazoeYasutoshi KubokiEiji ShinozakiHiroki HaraTomohiro NishinaYoshito KomatsuSatoshi YukiMasashi WakabayashiShogo NomuraAkihiro SatoTakeshi KuwataMasahito KawazuHiroyuki ManoYosuke TogashiHiroyoshi NishikawaTakayuki YoshinoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Napabucasin with pembrolizumab showed antitumor activity with acceptable toxicities for patients with MSS mCRC as well as MSI-H mCRC, although it did not meet the primary end point. The impact of related biomarkers on the efficacy warrants further investigations in the additional cohort.See related commentary by Nusrat, p. 5775.